December 19, 2023 12:31 PM EST
Pharma
FDA+

Mer­ck clinch­es pri­or­i­ty re­view for pneu­mo­coc­cal vac­cine, rais­ing stakes for Pfiz­er

Lia DeGroot

The FDA on Tues­day grant­ed Mer­ck pri­or­i­ty re­view for its in­ves­ti­ga­tion­al pneu­mo­coc­cal vac­cine, mak­ing strides ahead of Pfiz­er in the com­pa­nies’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times